Every man with prostate cancer deserves a better answer
New research reveals that up to 1 in 6 men with prostate cancer have a hereditary, disease-causing mutation¹.
Every man with prostate cancer deserves to know their germline status and recent changes now make that possible. Knowing your patient’s germline status early in the treatment journey not only helps guide treatment decisions, it could also qualify them for future, life-sustaining therapies should they progress to metastasis.
Did you know men with localized prostate cancer and BRCA mutations are²
6× more likely to die from prostate cancer within 5 years
4× more likely to develop prostate cancer metastasis within 5 years
Live ~7 years less
Ready to learn more?
Myriad germline testing impacts treatment decisions
Hereditary prostate cancer is frequently more aggressive than sporadic or familial prostate cancers, and this information should be factored into medical decision-making. Patients with germline mutations may be at risk for multiple primary tumors and hereditary cancer testing is the only way to know which patients are at risk.
Myriad germline testing can improve outcomes
PARP inhibitor therapy is now approved for men with HRR-mutated Metastatic Castration-Resistant Prostate Cancer. Genetic mutation status is the only way to determine if your metastatic prostate cancer patient is eligible for these new therapies.
Genetics and Risk Management
The Myriad Difference
Over 25 years as a leader in molecular diagnostics
In 1994, Myriad discovered the BRCA1 gene and subsequently introduced the first molecular diagnostic test for hereditary breast and ovarian cancer.
Hereditary germline testing is now standard-of-care in all breast and ovarian cancer patient workups and we are committed to making germline testing standard-of-care in prostate cancer. Myriad has since provided 5 million patients with life changing genetic information.
Myriad is committed to expanding access to germline testing for all men with prostate cancer and providing our customers with timely and actionable results.
To help meet the needs of your patient and practice, Myriad offers a variety of testing solutions to ensure that every man with prostate cancer gets a better answer.
BRACAnalysis CDx® can help determine which of your patients with prostate cancer are or may be appropriate for PARP Inhibitor therapy by identifying if they have a germline BRCA1/2 mutation. This test was designed to provide BRCA1/2 results quickly and accurately.
Myriad MyRisk® test is a 35-gene cancer panel that will provide patients with prostate cancer comprehensive information about their unique cancer. Using industry leading accuracy, unmatched turnaround time, and a lifetime commitment to patients, myRisk is an essential part of prostate cancer evaluations.
Ready to learn more?
Resources for your practice
- Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines Nicolosi et al. JAMA Oncol 2019
- Germline BRCA Mutations Are Associated With Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate Cancer. Castro et al. J Clin Oncol 31 (2013).
- Bratt O, et al. Clinical Management of Prostate Cancer in Men with BRCA Mutations. Eur Urol. 2015 Aug;68(2):194‐5
- NCCN® Clinical Practice Guidelines in Oncology – Genetic/Familial High-Risk Assessment: Breast and Ovarian V.3.2019.
- NCCN® Clinical Practice Guidelines in Oncology – Prostate Cancer V.2.2019.
*High/very high risk prostate cancer as defined by NCCN® Clinical Practice Guidelines in Oncology – Prostate Cancer V.2.2019.